This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sathya, G. Articles by MCDonnell, D. P. Search for Related Content PubMed PubMed Citation Articles by Sathya, G. Articles by MCDonnell, D. P.

Identification and Characterization of Novel Estrogen Receptor-ß-Sparing Antiprogestins

Department of Pharmacology and Cancer Biology (G.S., M.S.J., S.C.N., D.P.M.), Duke University Medical Center, Durham, North Carolina 27710; and Chemistry and Life Sciences (C.E.C.), Research Triangle Institute, Research Triangle Park, North Carolina 27709

Address all correspondence and requests for reprints to: Donald P. McDonnell, Department of Pharmacology and Cancer Biology, Duke University Medical Center, Box 3813, Durham, North Carolina 27710. E-mail: . donald.mcdonnell{at}duke.edu

The steroid hormones estrogen and progesterone together regulate the development and maintenance of the female reproductive system. The actions of these two hormones are mediated by their respective nuclear receptors located within overlapping cell populations in target organs. The molecular mechanism of action of these two hormones has been defined to a large extent using estrogen receptor (ER) and progesterone receptor (PR) antagonists. In the case of ER, the available antagonists are highly receptor selective. With respect to PR, however, the available antiprogestins also interact with the receptors for glucocorticoids, mineralocorticoids, and androgens. Whereas these cross-reactivities can usually be managed in studies of female reproductive function, it is the recent demonstration that RU486 is an effective antagonist of the ß-isoform of ER that suggested the need for more selective antiprogestins. In this study, we used cell-based transcriptional assays combined with screens using coactivator peptide analogs to identify two novel classes of antiprogestins that distinguish themselves from the antiprogestin RU486 in the manner they interact with PR. One class exhibits the characteristics of a pure antiprogestin in that its members bind to the receptor and induce a conformational change that prevents the presentation of two potential coactivator binding surfaces on the protein. The second class of compounds distinguish themselves from RU486 in that they are ERß sparing. When tested in vivo the ER-sparing antiprogestins were as effective as RU486 in suppressing superovulation. It is anticipated that the availability of these new antiprogestins will advance the studies of PR pharmacology in a manner similar to how the availability of selective ER modulators has helped the study of ER action.

This article has been cited by other articles:

				L. J. Lewis-Tuffin, C. M. Jewell, R. J. Bienstock, J. B. Collins, and J. A. Cidlowski Human Glucocorticoid Receptor {beta} Binds RU-486 and Is Transcriptionally Active Mol. Cell. Biol., March 15, 2007; 27(6): 2266 - 2282. [Abstract] [Full Text] [PDF]

				M. S. Jansen, S. C. Nagel, P. J. Miranda, E. K. Lobenhofer, C. A. Afshari, and D. P. McDonnell Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition PNAS, May 4, 2004; 101(18): 7199 - 7204. [Abstract] [Full Text] [PDF]

				G. Sathya, C.-y. Chang, D. Kazmin, C. E. Cook, and D. P. McDonnell Pharmacological Uncoupling of Androgen Receptor-mediated Prostate Cancer Cell Proliferation and Prostate-specific Antigen Secretion Cancer Res., November 15, 2003; 63(22): 8029 - 8036. [Abstract] [Full Text] [PDF]